Peer-influenced content. Sources you trust. No registration required. This is HCN.
Dana-Farber Cancer Institute
Reed-Sternberg cells harbor chromosome 9p24 amplification encoding PD-1 ligand, creating therapeutic vulnerability exploited by checkpoint inhibitors with remarkable clinical responses.
Hematology/Oncology May 27th 2025
MDLinx
In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.
Obstetrics & Gynecology March 31st 2025
Oncology News Central (ONC)
Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.
Oncology, Medical February 5th 2024
The ESMO Congress 2023 has highlighted how international studies in NSCLC are currently being reported at a rapid pace. This underscores the importance of staying updated on these advancements to provide optimal patient care.
Oncology, Medical October 23rd 2023
Discover how a novel combination therapy targeting EGFR and AXL proteins could revolutionize the treatment of head and neck squamous cell carcinoma and lung adenocarcinoma.
Oncology, Medical September 19th 2023
Medical Professionals Reference (MPR)
The FDA’s recent approval of Akeega, a combination therapy for BRCA-mutated mCRPC, marks a significant advancement in targeted treatment. This approval, based on the MAGNITUDE study, offers a new therapeutic option for patients, supported by robust clinical data.
Oncology, Medical August 21st 2023